Forbes Daily Briefing podcast

Best Of 2025: This Pharma Company Is Betting Big On A Chinese Ozempic Rival

0:00
5:11
Recuar 15 segundos
Avançar 15 segundos

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to develop novel medications in the U.S. when Chinese firms have probably already done it for you?

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mais episódios de "Forbes Daily Briefing"